Elsevier

The Lancet

Volume 359, Issue 9311, 23 March 2002, Pages 990-992
The Lancet

Commentary
Angiotensin blockade for hypertension: a promise fulfilled

https://doi.org/10.1016/S0140-6736(02)08062-5Get rights and content

First page preview

First page preview
Click to open first page preview

References (17)

There are more references available in the full text version of this article.

Cited by (43)

  • Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation

    2018, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Therefore, AT1 receptors and A-II biosynthesis mechanisms are targets for the development of new synthetic drugs and therapeutic treatment of various cardiovascular and such issues. Several non-peptide AT1 receptor antagonists have been described in the past few years, such as “sartans”, i.e. candesartan, irbesartan, valsartan, telmisartan and eprosartan; which are effective in the treatment of hypertension and associated cardiovascular disorders [9–15]. These approved drugs differ in their structure, pharmacological profile and efficacy.

  • Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives

    2018, Journal of Molecular Graphics and Modelling
    Citation Excerpt :

    Therefore, AT1 receptors and the A-II biosynthesis mechanisms are targets for the development of new synthetic drugs and therapeutic treatment of various cardiovascular and such diseases. In the past few years, several non-peptide AT1 receptor antagonists have been described as “sartans”, which are effective in the treatment of hypertension and cardiovascular disorders [9–15]. These approved drugs differ in their structure, pharmacological profile and efficacy.

  • Therapeutic role of toll-like receptor modification in cardiovascular dysfunction

    2013, Vascular Pharmacology
    Citation Excerpt :

    In an animal model of chronic stress, Eritoran inhibited NFkB activity and reduced stress-related myocardial injury (Wang et al., 2011b). Angiotensin II receptor blockers are commonly used in patients with cardiovascular diseases to lower blood pressure (Dahlof et al., 2002; Brunner and Gavras, 2002). In addition to its vasoconstrictor activity, angiotensin II increases reactive oxygen species and inflammatory mediators such as IL-6 and TNF-alpha.

  • Modern Drug Discovery and Development

    2009, Clinical and Translational Science
View all citing articles on Scopus
View full text